Literature DB >> 28528011

Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation.

Alec L Amram1, Grecia Rico2, Jonathan W Kim3, Murali Chintagumpala4, Cynthia E Herzog5, Dan S Gombos6, Patricia Chévez-Barrios7.   

Abstract

PURPOSE: A recent classification scheme for retinoblastoma vitreous seeds has shown promise in predicting treatment response. For the first time, we correlate this clinical classification scheme with its histopathologic features.
DESIGN: Retrospective review. PARTICIPANTS: Enucleated eyes received at the pathology department of the Retinoblastoma Center of Houston from 2010 to 2015.
METHODS: Macroscopic photographs of the enucleated eyes of patients with retinoblastoma were analyzed to select those with vitreous seeds. Cases with adequate material for clinicopathologic correlation were selected for further analysis, and clinical photographs were reviewed. Routine histopathologic slides were reviewed and compared with the clinical and macroscopic photographs. Seeds were classified as type 1 ("dust"), type 2 ("sphere"), or type 3 ("cloud"). To confirm the presence of macrophages, CD68 immunohistochemical staining was used. Synaptophysin was used to stain retinoblastoma cells. MAIN OUTCOME MEASURES: To correlate clinical vitreous seed type with histopathologic features.
RESULTS: A total of 14 eyes with adequate amounts of tumor seeds along with clinical and macroscopic photographic correlation were selected from a total of 138 eyes reviewed. Type 1 seeds consisted of individual viable tumor cells and scattered macrophages. Type 2 seeds consisted of 2 submorphologies: spheres with viable cells throughout and spheres with an outer rim of viable cells but necrotic cells centrally. Type 3 seeds were composed of more than 90% necrotic material admixed with few macrophages and viable cells at their outer rim. Untreated (8/14) and previously treated (6/14) eyes showed similar histopathologic features for each type of seeds. Treated eyes had more type 1 and 3 seeds.
CONCLUSIONS: We provide the first histopathologic correlation of the clinical classification scheme for vitreous seeds in retinoblastoma. "Dust" is formed by scattered single cells alternating with macrophages. "Spheres" with translucent centers contain multiple layers of viable tumor cells that shed single cells and may be more clinically aggressive. "Cloud" seeds are mostly composed of necrotic material, explaining their lack of therapeutic response. Pretreated eyes showed tumor seeds morphologically similar to untreated eyes. Knowledge of the underlying histopathology of vitreous seed types is a fundamental component of classification and may aid in understanding clinical response to treatment.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28528011     DOI: 10.1016/j.ophtha.2017.04.015

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.

Authors:  Arthur Aubry; Tao Yu; Rod Bremner
Journal:  Cell Death Discov       Date:  2020-01-20

Review 2.  A Review of Recurrent Retinoblastoma: Children's Hospital Los Angeles Classification and Treatment Guidelines.

Authors:  Jesse L Berry; Kaitlin Kogachi; A Linn Murphree; Rima Jubran; Jonathan W Kim
Journal:  Int Ophthalmol Clin       Date:  2019

3.  Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds.

Authors:  Zachary K Goldsmith; William Coppess; Andrew S Irvine; Kelley Yuan; Samuel R Barsh; Madison K Ritter; Matthew W McEwen; Jacqueline Flores-Otero; Aileen Garcia-Vargas; Magaly Martinez-Ferrer; Rachel C Brennan; Vanessa M Morales-Tirado; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-09-04       Impact factor: 4.799

4.  Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.

Authors:  Arthur Aubry; Tao Yu; Rod Bremner
Journal:  Cell Death Discov       Date:  2020-01-20

5.  Early Mechanisms of Chemoresistance in Retinoblastoma.

Authors:  Michelle G Zhang; Jeffim N Kuznetsoff; Dawn A Owens; Ryan A Gallo; Karthik Kalahasty; Anthony M Cruz; Stefan Kurtenbach; Zelia M Correa; Daniel Pelaez; J William Harbour
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

6.  Comprehensive Somatic Copy Number Analysis Using Aqueous Humor Liquid Biopsy for Retinoblastoma.

Authors:  Mary E Kim; Ashley Polski; Liya Xu; Rishvanth K Prabakar; Chen-Ching Peng; Mark W Reid; Rachana Shah; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Cancers (Basel)       Date:  2021-07-03       Impact factor: 6.639

7.  Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging.

Authors:  Ankit Singh Tomar; Paul T Finger; Brenda Gallie; Tero Kivelä; Ashwin Mallipatna; Chengyue Zhang; Junyang Zhao; Matthew Wilson; Rachel Brennan; Michala Burges; Jonathan Kim; Jesse L Berry; Rima Jubran; Vikas Khetan; Suganeswari Ganeshan; Andrey Yarovoy; Vera Yarovaya; Elena Kotova; Denis Volodin; Yacoub Yousef; Kalle Nummi; Tatiana L Ushakova; Olga V Yugay; Vladimir G Polyakov; Marco Antonio Ramirez-Ortiz; Elizabeth Esparza-Aguiar; Guillermo L Chantada; Paula Schaiquevich; Adriana C Fandiño; Jason C Yam; Winnie W Lau; Carol P Lam; Phillipa Sharwood; Sonia Moorthy; Quah Boon Long; Vera Adobea Essuman; Lorna A Renner; Ekaterina Semenova; Jaume Català-Mora; Maria Correa Llano; Elisa Carreras
Journal:  Br J Ophthalmol       Date:  2021-08-02       Impact factor: 5.908

8.  A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma.

Authors:  Duangporn Saengwimol; Duangnate Rojanaporn; Vijender Chaitankar; Pamorn Chittavanich; Rangsima Aroonroch; Tatpong Boontawon; Weerin Thammachote; Natini Jinawath; Suradej Hongeng; Rossukon Kaewkhaw
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.